{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125940","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.324169+00:00","generated_at":"2026-05-30T01:16:18.422118+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M","bullets":["FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.","Received RMAT designation for LX2006; completed enrollment in SUNRISE-FA Phase 1/2 (16 patients dosed to date).","LX2020 PKP2-ACM cohort 1 enrollment completed; initial safety/biodistribution data expected late Q1/Q2 2025.","Q3 net loss $29.5M ($0.89 per share) vs $20.1M year-ago; R&D $23.4M, G&A $8.1M.","Cash $157M expected into 2027; Tolga Tanguler (Alnylam exec) appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125940","json":"https://secwatch.observer/filing/0000950170-24-125940.json","markdown":"https://secwatch.observer/filing/0000950170-24-125940.md","text":"https://secwatch.observer/filing/0000950170-24-125940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/0000950170-24-125940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-20241111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:16:18.422118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7181d5c993","claim":"Tolga Tanguler was appointed as director at Lexeo Therapeutics, Inc..","evidence_excerpt":"On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/0000950170-24-125940-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}